地舒单抗相关非典型骨折的文献分析

郑永飞; 刘慧娜

doi:10.6039/j.issn.1001-0408.2023.16.15

您当前的位置：

首页 >

文章列表页 >

地舒单抗相关非典型骨折的文献分析

药物与临床 | 更新时间：2023-08-24

- 地舒单抗相关非典型骨折的文献分析
- Literature analysis of atypical fractures associated with denosumab
- 中国药房 2023年34卷第16期页码：1999-2002
- 作者机构：
  
  郑州市骨科医院药学部，郑州　450052
- 作者简介：
  
  主管药师。研究方向：医院药学。E-mail：zzu.zyf2006@163.com
  副主任药师。研究方向：临床药学。E-mail：47127444@qq.com
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.16.15
  中图分类号： R969.3
- 纸质出版日期：2023-08-30，
  
  收稿日期：2023-01-12，
  
  修回日期：2023-07-06，
扫描看全文
郑永飞,刘慧娜.地舒单抗相关非典型骨折的文献分析[J].中国药房,2023,34(16):1999-2002.

ZHENG Yongfei,LIU Huina.Literature analysis of atypical fractures associated with denosumab[J].ZHONGGUO YAOFANG,2023,34(16):1999-2002.
郑永飞,刘慧娜.地舒单抗相关非典型骨折的文献分析[J].中国药房,2023,34(16):1999-2002. DOI： 10.6039/j.issn.1001-0408.2023.16.15.

ZHENG Yongfei,LIU Huina.Literature analysis of atypical fractures associated with denosumab[J].ZHONGGUO YAOFANG,2023,34(16):1999-2002. DOI： 10.6039/j.issn.1001-0408.2023.16.15.

摘要

目的

探讨地舒单抗相关非典型骨折（AF）的发生特点和规律，为临床合理用药提供参考。

方法

计算机检索PubMed、Web of Science、中国知网、万方数据、维普网，收集地舒单抗相关AF的个案报道，并进行描述性分析。

结果

共纳入文献19篇，涉及患者20例，其中男性3例、女性17例，平均年龄（69.80±15.39）岁。20例患者中，14例患者的原患疾病为骨质疏松症，6例为实体瘤骨转移和骨巨细胞瘤；AF发生时间为使用地舒单抗后3～132个月，平均（42.14±29.49）个月；14例患者在发生AF前出现了前驱症状；3例患者为尺骨骨折，17例为股骨骨折。绝大多数患者停药并采用手术固定治疗后，恢复良好，但有部分患者出现骨折延迟愈合。

结论

临床在长期使用地舒单抗时应警惕AF的发生；当患者出现大腿、腹股沟、髋关节和前臂疼痛等前驱症状时应及时就医，以保障用药安全。

Abstract

OBJECTIVE

To investigate the characteristics and regularity of denosumab-associated atypical fractures （AF）， so as to provide references for clinical rational use of drugs.

METHODS

The case reports of AF related to denosumab were retrieved from PubMed， Web of Science， CNKI， Wanfang data and VIP databases， and the reports were descriptively analyzed.

RESULTS

A total of 19 references were retrieved， including 20 patients. There were 3 males and 17 females， with an average age of （69.80±15.39） years. Among 20 patients， primary diseases of 14 patients were osteoporosis， and 6 cases were malignant tumor bone metastasis and giant cell tumor of bone. The occurrence time of AF ranged from 3 to 132 months after the administration of denosumab， with an average of （42.14±29.49） months. Fourteen cases had prodromal symptoms before AF. There were 3 cases of ulna fractures， and the remaining 17 cases were femoral fractures. The vast majority of patients recovered well after discontinuing medication and undergoing surgical fixation， but some patients experienced delayed fracture healing.

CONCLUSIONS

Long-term use of denosumab should be vigilant against AF. When patients experience prodromal symptoms such as thigh， groin， hip joint and forearm pain， they should seek medical attention in a timely manner to ensure medication safety.

关键词

地舒单抗非典型骨折骨质疏松症文献分析

Keywords

atypical fracturesosteoporosisliterature analysis

references

KENDLER D L，COSMAN F，STAD R K，et al. Denosumab in the treatment of osteoporosis：10 years later：a narrative review[J]. Adv Ther，2022，39（1）：58-74.

CADIEUX B，COLEMAN R，JAFARINASABIAN P，et al. Experience with denosumab（XGEVA®）for prevention of skeletal-related events in the 10 years after approval[J]. J Bone Oncol，2022，33：100416.

夏维波. 地舒单抗在骨质疏松症临床合理用药的中国专家建议[J]. 中华骨质疏松症和骨矿盐疾病杂志，2020，13（6）：499-508.

中国抗癌协会泌尿男生殖系肿瘤专业委员会. 地舒单抗在前列腺癌骨转移患者中的临床应用规范[J/OL]. 肿瘤综合治疗电子杂志，2021，7（3）：17-21[2021-08-20]. http：//www.jmcm2018.com/CN/Y2021/V7/I3/17http://www.jmcm2018.com/CN/Y2021/V7/I3/17. DOI：10.12151/ JMCM.2021.03-04http://dx.doi.org/10.12151/JMCM.2021.03-04.

牛晓辉. 骨巨细胞瘤的地舒单抗药物治疗[J]. 中国骨与关节杂志，2021，10（2）：81-84.

SHANE E，BURR D，ABRAHAMSEN B，et al. Atypical subtrochanteric and diaphyseal femoral fractures：second report of a task force of the American Society for Bone and Mineral Research[J]. J Bone Miner Res，2014，29（1）：1-23.

STARR J，TAY Y K D，SHANE E. Current understanding of epidemiology，pathophysiology，and management of atypical femur fractures[J]. Curr Osteoporos Rep，2018，16（4）：519-529.

YANG S P，KIM T W，BOLAND P J，et al. Retrospective review of atypical femoral fracture in metastatic bone di-sease patients receiving denosumab therapy[J]. Oncologist，2017，22（4）：438-444.

WARREN A M，EBELING P R，GRILL V，et al. Bilateral atypical femoral fractures during denosumab therapy in a patient with adult-onset hypophosphatasia[J]. Endocrinol Diabetes Metab Case Rep，2021，2021：21-0096.

THOMPSON R N，ARMSTRONG C L，HEYBURN G. Bilateral atypical femoral fractures in a patient prescribed denosumab：a case report[J]. Bone，2014，61：44-47.

NEZU K，ENDO Y，KATAYAMA H，et al. Case of atypical femoral fractures that mimicked the typical imaging findings of prostate cancer-induced bone metastasis[J]. IJU Case Rep，2019，2（6）：303-306.

KUMAR S，CHANG R，REYES M，et al. Atypical femoral fracture in a bisphosphonate-naive patient on denosumab for osteoporosis[J]. Arch Osteoporos，2022，17（1）：131.

SELGA J，NUÑEZ J H，MINGUELL J，et al. Simulta-neous bilateral atypical femoral fracture in a patient re-ceiving denosumab：case report and literature review[J]. Osteoporos Int，2016，27（2）：827-832.

DUPAIX J P，OPANOVA M I，LEE L S K，et al. Deno-sumab-associated peri-implant atypical femur fracture：a case report[J]. Hawaii J Health Soc Welf，2019，78（11 Suppl 2）：47-51.

GOH J K M，KOH J S B，NG A C M，et al. Bilateral atypical femur fractures after denosumab in a bisphosphonate naive patient：a case report[J]. Calcif Tissue Int，2022，111（1）：96-101.

AUSTIN D C，TORCHIA M T，KLARE C M，et al. Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab[J]. Acta Orthop，2017，88（3）：351-353.

KHOW K S F，YONG T Y. Atypical femoral fracture in a patient treated with denosumab[J]. J Bone Miner Metab，2015，33（3）：355-358.

DRAMPALOS E，SKARPAS G，BARBOUNAKIS N，et al. Atypical femoral fractures bilaterally in a patient receiving denosumab[J]. Acta Orthop，2014，85（1）：3-5.

SUGIHARA T，KOIZUMI M，HAYAKAWA K，et al. Impending atypical femoral fracture in a patient of breast cancer with bone metastases receiving long-term denosumab[J]. Clin Nucl Med，2018，43（5）：365-366.

SCHILCHER J，ASPENBERG P. Atypical fracture of the femur in a patient using denosumab：a case report[J]. Acta Orthop，2014，85（1）：6-7.

PAPARODIS R，BUEHRING B，PELLEY E M，et al. A case of an unusual subtrochanteric fracture in a patient receiving denosumab[J]. Endocr Pract，2013，19（3）：e64-e68.

VILLIERS J，CLARK D W，JESWANI T，et al. An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab[J]. Case Rep Rheumatol，2013，2013：249872.

PIPONOV H I，GOLDSTEIN J M，EISENBERG G M. Multiple ipsilateral femoral stress fractures in a patient taking denosumab for osteoporosis：a case report[J]. Osteoporos Int，2020，31（11）：2263-2267.

NASCA V，FREZZA A M，MOROSI C，et al. Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture：a case report and review of literature[J]. Front Oncol，2022，12：953149.

BINKLEY N，GOEL H，SHIVES E，et al. A probable atypical ulnar fracture in a man receiving denosumab[J]. Bone，2021，143：115726.

MURAI A，TADA，NAKAJIMA T，et al. Case report：prophylactic plate fixation for incomplete atypical ulnar fractures resulting from the use of denosumab for bone meta-stases[J]. Front Endocrinol（Lausanne），2022，12：798653.

OKUBO N，YOSHIDA T，OHARA M，et al. Atypical ulnar fracture in an older woman with osteoporosis with a five-year history of denosumab treatment：a case report[J]. J Hand Surg Asian Pac Vol，2022，27（5）：928-932.

BLACK D M，GEIGER E J，EASTELL R，et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates[J]. N Engl J Med，2020，383（8）：743-753.

YAMAMOTO N，YAMAUCHI M，NODA T，et al. Atypical ulnar fracture with atypical femoral fracture：a case report and literature review[J]. J Orthop Sci，2022，27（6）：1354-1358.

BANFFY M B，VRAHAS M S，READY J E，et al. Non-operative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures[J]. Clin Orthop Relat Res，2011，469（7）：2028-2034.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

肝癌合并HBV感染患者使用富马酸替诺福韦二吡呋酯致肾损伤1例并文献分析

临床药师参与1例左氧氟沙星致超敏反应的药学监护及文献分析

度普利尤单抗致眼部相关不良反应文献分析

舒尼替尼致肾病综合征文献分析

ICU常用静脉药物配伍稳定性的文献分析